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abstract
PURPOSE Anal cancer risk is substantially higher among HIV-infected men who have sex with men (MSM) as
compared with other reproductive-age adults, but screening is rare across sub-Saharan Africa. We report the use
of high-resolution anoscopy (HRA) as a first-line screening tool and the resulting early outcomes among MSM in
Abuja, Nigeria.
METHODS From August 2016 to August 2017, 424 MSM enrolled in an anal cancer screening substudy of
TRUST/RV368, a combined HIV prevention and treatment cohort. HRA-directed biopsies were diagnosed by
histology, and ablative treatment was offered for high-grade squamous intraepithelial lesions (HSIL). HRA
proficiency was assessed by evaluating the detection of squamous intraepithelial lesions (SIL) over time and the
proportion biopsied. Prevalence estimates of low-grade squamous intraepithelial lesions and HSIL with 95% CIs
were calculated. Multinomial logistic regression was used to identify those at the highest risk of SIL.
RESULTS Median age was 25 years (interquartile range [IQR], 22-29), median time since sexual debut was
8 years (IQR, 4-12), and 59% (95% CI, 54.2% to 63.6%) were HIV infected. Rate of detection of any SIL
stabilized after 200 screenings, and less than 20% had two or more biopsies. Preliminary prevalence estimates
of low-grade squamous intraepithelial lesions and HSIL were 50.0% (95% CI, 44.7% to 55.3%) and 6.3% (95%
CI, 4.0% to 9.3%). HIV infection, at least 8 years since anal coital debut, concurrency, and external warts were
independently statistically associated with SIL.
CONCLUSION Proficiency with HRA increased with experience over time. However, HSIL detection rates were
low, potentially affected by obstructed views from internal warts and low biopsy rates, highlighting the need for
ongoing evaluation and mentoring to validate this finding. HRA is a feasible first-line screening tool at an MSM-
friendly health care facility. Years since anal coital debut and external warts could prioritize screening.
J Global Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Anal cancer risk is 52-fold higher in HIV-infected men
who have sex with men (MSM) in the United States
compared with the general population,1 and anal high-
grade squamous intraepithelial lesions (HSIL) are
more likely to progress than to regress with HIV
coinfection.2 The syndemic of HIV and high-risk hu-
man papillomavirus (HR-HPV) drives the increasing
incidence of anal cancer among MSM in the United
States.1 We have reported previously, among MSM
receiving care at a community-engaged health care
facility in Abuja, Nigeria, an HIV prevalence of 45%
and a HR-HPV prevalence of 90% for those living with
HIV.3,4 As HIV-infected MSM in sub-Saharan Africa
age with the use of effective antiretroviral therapy, an
increasing anal cancer incidence can be expected,
paralleling current trends in the United States.1
High-resolution anoscopy (HRA) is a sensitive di-
agnostic test but is generally used as a second-line
screening tool after a positive anal Pap test because of
its steep learning curve.5-8 In Nigeria, however, liquid
cytology is not available, and many factors would
hinder accurate and timely diagnosis; therefore, we
deferred to HRA as the most sensitive and cost-
effective method.8,9 A colposcope helps the exam-
iner visualize biopsy areas suspected to be HSIL or
cancer in the anal canal and the perianal areas. Ab-
lative therapy is used to treat biopsy-proven anal HSIL,
extrapolating from data showing that treatment of
cervical HSIL in women reduces the incidence of
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cervical cancer. Challenges with mastering HRA include
understanding the topographic anatomy of the anal canal
and working in a three-dimensional space with good eye-
hand coordination.5 Lesions may be obscured by internal
warts, hemorrhoids, or folds.5 HRA also requires a co-
ordinated team of specialists to optimize care, including
a skilled pathologist and a surgeon capable of performing
excisional biopsies, treating extensive HSIL, and managing
complicated cases.5 Despite these challenges, we decided
to assess the feasibility of HRA in a low-resource setting
with high rates of HIV and HR-HPV.
Even with specialized training in HRA and a skilled in-
terdisciplinary team, the success of a screening program
may be further complicated by cultural environments in
which same-sex practices are stigmatized or criminalized.
NigerianMSM face high levels of discrimination andmust be
cautious of environments in which their sexual identity could
be disclosed.10,11 Homophobia is also problematic in
Nigerian health care settings; nearly a quarter of medical
students in one study believedMSM should be denied health
care services.12 The objective of this study was to evaluate
participant acceptability of and clinician proficiency with
using HRA as a first-line screening tool at an MSM-friendly
community-engaged health care facility in Nigeria. Sec-
ondary objectives included evaluating the prevalence and
correlates of anal squamous intraepithelial lesions (SIL).
METHODS
Training and Mentoring
Two Nigerian physicians, one trained in infectious diseases
and the other in surgery, attended a 4-day comprehensive
colposcopy and high-resolution anoscopy training course
conducted by the American Society for Colposcopy and
Cervical Pathology in Providence, RI. After the course, the
infectious disease physician shadowed experienced HRA
practitioners for 4 days at the Anal Neoplasia Clinic, Re-
search and Education Center at the University of California,
San Francisco (UCSF) Helen Diller Family Comprehensive
Cancer Center. A Nigerian pathologist also traveled to San
Francisco to receive mentoring on anal cytologic and
histologic samples at the UCSF Department of Pathology.
UCSF physicians were available throughout the study for
guidance, and one conducted 2 week-long, on-site men-
toring sessions in Nigeria, including one focused on
screening techniques 3 months after study initiation and
a second on treatment-oriented session at study closure.
Study Design and Population
Anal cancer screening was performed in Abuja, Nigeria, as
a substudy of the previously described TRUST/RV368
cohort study.13,14 In brief, TRUST/RV368 recruits MSM
using respondent-driven sampling into comprehensive HIV
and sexually transmitted infection prevention, treatment,
and care. Between August 2016 and August 2017, par-
ticipants of TRUST/RV368 who were 18 years of age or
older were educated on the rationale and procedures of the
screening study. Interested men were enrolled if they
provided separate informed consent in English or Hausa.
Exclusion criteria included an allergy to lidocaine or iodine,
as well as any medical condition that could increase the risk
associated with HRA or anal biopsy, such as a bleeding
disorder.
The anal cancer screening substudy included a training
period, during which the Nigerian physician performed at
least 100 HRAs before additional on-site mentoring by
UCSF staff. Prior data have suggested that this number of
HRAs is sufficient to achieve proficiency.15 Once training
was complete, at least 350 men were screened to estimate
the prevalence and correlates of SIL. Men seen during
training were allowed to be rescreened.
Clinical Procedures
All participants completed a questionnaire that captured
data on smoking, anal cancer symptoms, and sexual be-
haviors. Additional clinical and behavioral data were
CONTEXT
Key Objective
Could high-resolution anoscopy (HRA) be used as a first-line screening tool for men at high risk of anal cancer across sub-
Saharan Africa?
Knowledge Generated
HRA screening was highly attended, with more than 500 screenings among men who have sex with men (MSM) in the context
of a culturally and clinically competent health care facility providing HIV and sexually transmitted infection care in Nigeria.
HRA clinical proficiency improved with experience, although preliminary estimates of high-grade squamous intraepithelial
lesions were low, suggesting the need for ongoing evaluation and clinical mentorship. MSM with anal warts and at least
8 years since anal coital debut were at highest risk of high-grade squamous intraepithelial lesions; therefore, these are
potential indications for priority screening.
Relevance
With sufficient mentorship, HRA represents an effective secondary cancer prevention approach for MSM even in the context of
challenging social environments, suggesting the need for broader evaluation of implementation strategies.
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obtained from the parent TRUST/RV368 study. Partici-
pants underwent digital anorectal examination, swabbing of
the anal canal for future HPV testing, HRA, and HRA-
directed biopsies of abnormalities for histologic confirma-
tion. Cytology slides were introduced as a quality control
measure after training to capture any missed HSIL. Liquid-
based cytology was unavailable, so anal swabs were
smeared on slides and fixed in 100% alcohol. Cytology
slides were classified using the 2001 Bethesda System,
and cells were interpreted as negative, atypical squamous
cells of undetermined significance, atypical squamous
cells, cannot exclude HSIL, low-grade squamous intra-
epithelial lesions (LSIL), or HSIL.16
During HRA, 5% acetic acid and Lugol’s iodine were ap-
plied to the squamocolumnar junction to visualize abnor-
malities. Only men with acetowhite lesions underwent
biopsies. The biopsy specimens were fixed in formalin and
embedded in paraffin before processing for routine he-
matoxylin and eosin histopathologic assessment. Biopsy
specimens were classified according to the Lower Ano-
genital Squamous Terminology17 as benign, low-grade
squamous intraepithelial neoplasia (LSIL), HSIL, or squa-
mous cell carcinoma. Ablative therapy with hyfrecation was
offered for those with biopsy-diagnosed HSIL.
After study completion, UCSF reviewed 21 histologic
samples representing benign to HSIL. Percent agreement
and unweighted Kappa were calculated to compare con-
sistency in histology diagnosis between the two institutions.
Ethical Considerations
The institutional review board at the Nigerian Federal
Capital Territory Health Research Ethics Committee, the
Clinical Research Committee at the University of Maryland
Marlene and the Stewart Greenebaum Comprehensive
Cancer Center, the University of Maryland Baltimore, and
the University of California San Francisco institutional re-
view board reviewed and approved the research protocol.
Statistical Analyses
The prevalence of detected anal SIL and the proportion
biopsied between training and screening were used as
metrics to assess proficiency with HRA. Any differences in
participants between training and screening were evaluated
using Pearson’s χ2 and Fisher’s exact tests. HRA proficiency
was expected to be achieved after performing the procedure
on at least 100 men.15 Stabilization of the prevalence of LSIL
and HSIL was used as an indicator of proficiency6; to this
end, prevalence of any SIL and 95% CIs were estimated for
12 consecutive intervals throughout the year. Each interval
was made up of 43 to 44 men. The prevalence and 95% CIs
were plotted at the midpoint of each interval and fitted to
a standard growth curve to approximate a learning curve.
The primary outcome of screening was a multinomial
categorization of anal dysplasia: benign, LSIL, or HSIL.
Benign outcomes included those who did not undergo
a biopsy during HRA because no lesions were seen. His-
tology determined the final diagnosis during training.
During screening, a composite diagnosis was generated
from the worst grade of either cytology or histology. Cyto-
logic diagnoses of atypical squamous cells of undetermined
significance were categorized as negative/benign.
Data collected after training were used to evaluate predictors
of anal SIL. Demographic characteristics included age,
education, marital status, sexual orientation, and HIV status.
Behavioral characteristics included smoking, preferred
sexual position (anal insertive, anal receptive, or both), years
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FIG 1. High-resolution anoscopy screenings by month.
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since anal coital debut, lifetime number of receptive part-
nerships, transactional sex, and concurrency. Transactional
sex was defined as having exchanged anal or oral sex for
things wanted or needed such as money, drugs, food,
shelter, or transportation.18 Concurrency was defined as
havingmultiple sex partners at the same time in the past year
(both men and women). Clinical characteristics included
self-reported swollen or tender lymph nodes around the
groin area, any hardening or narrowing of the anal passage or
stenosis, anal herpes, and external anal warts at the time of
HRA.Nucleic acid amplification testing was performed at the
visit before HRA to diagnose anorectal or urethral Neisseria
gonorrhea and/or Chlamydia trachomatis.
Crude differences in participant characteristics by anal SIL
during screening were compared using Pearson’s χ2 and
Fisher’s exact tests. Bivariate and multivariable multinomial
logistic regression was used to estimate odds ratios and 95%
CIs. All variables associated with anal SIL in bivariate analysis
(P≤ .10) were included in themultivariablemodel. Variables
that were insignificant (P≥ .05) were removed in a backward
TABLE 1. Characteristics of Nigerian Men Who Have Sex With Men During Training and Screening
Characteristic Training (n = 122) Screening (n = 366) P*
HIV status < .01
Uninfected 26 (21.3) 159 (43.4)
Infected 96 (78.7) 207 (56.6)
Sexual position .04
Insertive 13 (10.7) 75 (20.8)
Receptive 15 (12.3) 46 (12.7)
Both 94 (77.1) 240 (66.5)
Years since anal coital debut .98
≤ 7 59 (50.4) 176 (50.6)
≥ 8 58 (49.6) 172 (49.4)
Lifetime No. of receptive sex partners .27
≤ 10 71 (64.0) 249 (70.0)
≥ 11 40 (36.0) 109 (30.0)
Concurrent sexual partnerships .01
None 32 (26.2) 120 (33.1)
Men only 54 (44.3) 108 (29.8)
Both men and women 36 (29.5) 135 (37.2)
Ever had anal herpes < .01
No 89 (81.7) 329 (95.6)
Yes 20 (18.4) 15 (4.4)
External warts observed during HRA < .01
No 105 (86.8) 263 (72.1)
Yes 16 (13.2) 102 (28.0)
Total No. of anal biopsies 21 257 < .01
0 104 (85.3) 179 (48.9)
1 15 (12.3) 121 (33.1)
2 3 (2.5) 62 (16.9)
3 0 (0.0) 4 (1.1)
Anal dysplasia† < .01
Benign 107 (89.9) 159 (43.7)
LSIL 12 (10.1) 182 (50.0)
HSIL 0 (0.0) 23 (6.3)
NOTE. Data are presented as No. (%). Bold indicates P , .05.
Abbreviations: HRA, high-resolution anoscopy; HSIL, high-grade squamous intraepithelial lesions; LSIL, low-grade squamous intraepithelial lesions.
*Pearson’s χ2 and Fisher’s exact tests.
†Worse diagnosis between cytology and histology. For cytology, smears were fixed in alcohol and collected only during screening.
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stepwise approach to obtain the most efficient model.
Lifetime number of receptive partners and sexual position
were not retained because of strong correlations with years
since anal coital debut and external anal warts. Observations
with missing covariates accounted for less than 5% of the
total sample and were retained in the multivariable analysis.
Data were analyzed using Stata Statistical Software, Release
13 (StataCorp, College Station, TX).
RESULTS
Of 444 men eligible for screening, 424 (95%) participated.
The median age was 25 years (interquartile range [IQR],
22-29 years), and the median time since anal coital debut
was 8 years (IQR, 4-12 years). Nearly 60% (250 of 424)
were HIV infected, with a median CD4 of 464 count/mm3
(IQR, 299-626 count/mm3) and a median HIV RNA viral
load of 27 copies/mL (IQR, 20-7,946 copies/mL). Fifty-
eight participated in training alone, 302 participated in
screening alone, and 64 participated in both. For men
multiply screened, only the most recent diagnosis was
included in the modeling. In total, 525 screenings were
conducted (Fig 1), with five missing histology diagnoses.
Compared with the men screened, those during training were
more likely to beHIV infected, hadmore receptive sex partners,
had more concurrent partnerships with strictly men, and were
more likely to self-report anal herpes, but they were less likely to
have external warts (Table 1). Only 15% of men during training
underwent at least one biopsy compared with 51% of men
during screening. Diagnosis for any SIL grew linearly for the first
200 screenings, and prevalence estimates stabilized for the
remainder of the study (Fig 2). The prevalence of LSIL was
10.1% (95% CI, 5.3% to 17.0%) during training and 50.0%
(95% CI, 44.7% to 55.3%) during screening. HSIL was not
diagnosed during training and was 6.3% (95% CI, 4.0% to
9.3%) during screening (Fig 3). HSIL was detected more
among HIV-infected than among HIV-uninfected men (8% v
4%, P , .01). One case of HSIL was diagnosed by cytology
and the rest by histology. Agreement in the histology diagnoses
between UCSF and Nigeria was 71% (Kappa = 0.56; 95% CI,
0.26 to 0.86), suggesting moderate agreement. The histologic
diagnosis was not altered if discrepant with UCSF to avoid
introducing bias. Sixty-one percent (14 of 23) of the cases of
HSIL returned for ablative treatment.
In the crude analysis, a higher proportion of men with LSIL
or HSIL had HIV, 8 or more years since anal coital debut,
more lifetime partners, any concurrency, and external warts
compared with those with a benign diagnosis. A higher
proportion of men with HSIL had urethral STIs relative to
men with a benign or LSIL diagnosis (Table 2). Five HSILs
were detected among men with urethral STIs; all these
men reported engaging in receptive sex. In the multivari-
able analysis, men had an increased odds of LSIL when
they had HIV (P = .02), concurrent partnerships with men
(P , .01), and external warts (P , .01). Urethral STIs
(P = .01), external warts (P, .01), and an anal coital debut
of more than 8 years (P = .04) increased the odds of HSIL
(Table 3).
DISCUSSION
Anal cancer screening using HRA as a first-line screening
tool was well accepted, with 95% enrollment in the program
among MSM attending a community-engaged health care
facility in Abuja, Nigeria. Previous studies have reported on
the challenge of conducting HRA5-8 and have recom-
mended quality assurance metrics of 100 or more HRAs
per year and identifying 50 or more cases of HSIL.15 Our
team conducted more than 500 HRAs in 1 year, meeting
the recommended volume of screenings, and diagnosed
23 cases of HSIL.15 To better understand our clinician’s
level of proficiency given the low number of HSILs, we
evaluated the prevalence of detecting any SIL over time.6
Similar to a prior study in the Netherlands,6 200 screenings
were needed before the clinician consistently diagnosed
the same prevalence of any SIL over time.6,8 Our HSIL
prevalence was consistent with that observed in some of the
first studies of HRA19,20 but may become higher once the
clinician achieves a similar S-shaped curve for HSIL de-
tection. Monitoring diagnostic prevalence6 over time allows
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TABLE 2. Characteristics of Nigerian Men Who Have Sex With Men During Screening
Characteristic Benign (n = 159) LSIL (n = 182) HSIL (n = 23) P*
HIV status , .01
Uninfected 91 (57.2) 60 (33.0) 7 (30.4)
Infected 68 (42.8) 122 (67.0) 16 (69.6)
Age, years .23
≤ 24 79 (49.7) 68 (37.4) 11 (47.8)
25-34 65 (40.9) 91 (50.0) 10 (43.5)
≥ 35 15 (9.4) 23 (12.6) 2 (8.7)
Education .10
≤ Senior secondary 94 (59.9) 88 (48.4) 13 (56.5)
≥ Tertiary 63 (40.1) 94 (51.7) 10 (43.5)
Marital status .42
Never 143 (91.7) 159 (87.4) 21 (91.3)
Ever 13 (8.3) 23 (12.6) 2 (8.7)
Currently smoke .60
No 124 (79.0) 143 (78.0) 16 (69.6)
Yes 22 (21.0) 40 (22.0) 7 (30.4)
Sexual orientation .39
Bisexual 126 (80.8) 136 (74.7) 17 (73.9)
Homosexual 30 (19.2) 46 (25.3) 6 (26.1)
Sexual position .07
Insertive 41 (26.0) 32 (18.0) 1 (4.4)
Receptive 16 (10.1) 27 (15.2) 3 (13.0)
Both 101 (63.9) 119 (66.9) 19 (82.6)
Years since anal coital debut .02
≤ 7 86 (58.1) 82 (46.6) 7 (31.8)
≥ 8 62 (41.9) 94 (53.4) 15 (68.2)
Lifetime No. of receptive sex partners .05
≤ 10 114 (73.1) 122 (68.9) 11 (47.8)
≥ 11 42 (26.9) 55 (31.1) 12 (52.2)
Transactional sex .28
No 95 (64.6) 114 (65.1) 10 (47.6)
Yes 52 (35.4) 61 (34.9) 11 (52.4)
Concurrent sexual partnerships .02
None 56 (35.9) 57 (31.3) 6 (26.1)
Men only 32 (20.5) 67 (36.8) 8 (34.8)
Both men and women 68 (43.6) 58 (31.9) 9 (39.1)
Any swollen or tender lymph nodes in groin area .34
No 132 (83.5) 151 (83.4) 22 (95.7)
Yes 26 (16.5) 30 (16.6) 1 (4.4)
Any hardening or narrowing of the anal passage or stenosis .52
No 117 (75.0) 135 (74.6) 19 (86.4)
Yes 39 (25.0) 46 (25.4) 3 (13.6)
(Continued on following page)
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an assessment of clinician progress on the part of the
learning curve where experience is being gained.
Another metric for evaluating clinical capacity is monitoring
the proportion of men undergoing a biopsy. Hillman et al15
suggest performingmore than one biopsy for each newpatient
depending on risk and prior screening experiences. Our bi-
opsy rate was 15% during training, and 3% had more than
one biopsy. Given the higher risk of HSIL observed during
training, the low biopsy rate of the first 122 men indicates that
some SIL may have been missed, confirming the time and
volume needed to master HRA. The clinician’s biopsy rate
increased to 51% during the pilot, but the multiple biopsy rate
was less than 20%, and the detection of HSIL was low. Ad-
ditional consultation with an experienced HRA clinician and
the pathologist could improve the clinician’s technique. An-
other study reported a similar range of biopsy rates for different
clinics, from 17% to 55%.7 In that study, the men were older,
wereHIV infected, and hadmany lifetime partners, and yet the
study reported anHSIL prevalence of only 10%. If biopsy rates
increase from 20% to 50%, then the clinic is improving, but it
may be an indication that the study is yet to develop adept
screening procedures as outlined by Hillman et al.15 Our HSIL
prevalence of 6% with more training may rise to as high as
15%, as seen in a study population with a similar age,21 but
not 20% to 40% as seen in oldermen.22-26 Biopsy rates are an
additional indication of proficiency and improve the in-
terpretation of reported prevalence estimates across studies.
Having external warts at the time of screening was the
strongest independent risk factor for LSIL or HSIL. Warts may
indicate receptive sexual practices, potential exposure to
oncogenic HPV alongside wart-associated HPVs, or an im-
mune systempredisposed to poor clearancewith higher risk of
active or persistent HPV.27 Prior studies have found that the
prevalence of anal warts and HSIL is much higher during HIV
infection.28-30 In some cases, lesions that seem visually to be
LSIL or benign warts also contain histologically defined
HSIL.31-33 Genital warts are associated with an increased risk
of anal cancer,34-36 and this risk is sustained even 10 years
after diagnosis.35 Visualization of anal warts on physical ex-
amination may be considered an indication for health care
providers to conduct HRA for anal cancer screening.
Our study enrolled a much younger population compared
with other HRA clinics, but many of the men had been
engaging in anal sex for enough time to develop HSIL.
Having 8 or more years since anal coital debut was in-
dependently associated with the presence of HSIL and
trended toward an association with LSIL (P = .08). As-
suming that the natural history of HR-HPV is similar, this
exposure time parallels the finding in women in which
several years of persistent HR-HPV was associated with
developing high-grade lesions.37 Some studies have eval-
uated age at coital debut as a precursor of HSIL, but it did
not manage to demonstrate significant predictive value.21,38
Other studies evaluated age and found mostly a null
relationship,2,25,39 whereas one reported a protective
effect.22 Years since anal coital debut, instead of age,
potentially indicates a person’s exposure history to HR-HPV
and could be used by clinicians in anMSM-friendly clinic to
identify men for screening.
Concurrent sexual partnerships with men only was an
independent predictor of LSIL but not HSIL (P = .13).
LSIL is an active, transient HPV infection that may be
indicative of a recent exposure to HPV.17 HSIL, in con-
trast, is indicative of a persistent infection with HR-
HPV.17 Therefore, recent sexual behavior, as seen with
concurrency, may be more associated with LSIL than
with HSIL. Consistent with our study, a study by
Machalek et al25 found that recent receptive practices
TABLE 2. Characteristics of Nigerian Men Who Have Sex With Men During Screening (Continued)
Characteristic Benign (n = 159) LSIL (n = 182) HSIL (n = 23) P*
Ever had anal herpes .87
No 143 (95.3) 164 (96.5) 21 (95.5)
Yes 7 (4.7) 6 (3.5) 1 (4.6)
Rectal STIs at last visit .64
No 119 (76.8) 146 (80.7) 19 (82.6)
Yes 36 (23.2) 35 (19.3) 4 (17.4)
Urethral STIs at last visit .01
No 144 (92.3) 172 (95.0) 18 (78.3)
Yes 12 (7.7) 9 (5.0) 5 (21.7)
External warts observed during HRA , .01
No 145 (91.8) 105 (57.7) 12 (52.2)
Yes 13 (8.2) 77 (42.3) 11 (47.8)
NOTE. Data are presented as No. (%). N = 364 (missing two histology diagnoses).
Abbreviations: HRA, high-resolution anoscopy; HSIL, high-grade intraepithelial lesions; LSIL, low-grade squamous intraepithelial lesions; STIs,
sexually transmitted infections (including Neisseria gonorrhea and Chlamydia trachomatis).
*Pearson’s χ2 and Fisher’s exact tests.
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were independently associated with HSIL-AIN2 but not
HSIL-AIN3. Because HSIL-AIN2 are equivocal lesions
that fall between LSIL and HSIL, they may have an active
transient component to their infection. More importantly,
restricting analyses to focus only on HSIL7,22,25 limits our
ability to disentangle factors that may be associated with
either of these lesions, because they may represent
different manifestations of HPV.
This study has some limitations. There was a low rate of
diagnosis of HSIL. Many of the men had internal warts that
potentially obstructed the view of the flatter lesions of
HSIL.33 Earlier training in the treatment of internal warts
may have helped improve the visibility and diagnosis of
HSIL. In the quality assurance and control review of
histologic diagnoses, the wide CIs of the Kappa statistic,
resulting from the small sample size, limited its usefulness.
Persistent HPV-16 confers the highest risk of HSIL,25,40 but
testing for type-specific HPVs is ongoing. Finally, the risk
factor analysis was cross-sectional and could not assess
temporality.
Anal cancer screening was implemented successfully as
a first-line screening tool in an MSM-friendly health care
facility in Nigeria, although additional mentoring and time
might have improved the quality of the HRA. HIV, con-
currency, early coital debut, and external warts were in-
dependently associated with anal dysplasia. If anal cancer
screening proves beneficial, these factors may help risk-
stratify men.
TABLE 3. Bivariable and Multivariable Associations of HIV and Other Correlates With Anal Dysplasia During Screening
LSIL HSIL
Characteristic Unadjusted OR (95% CI) Adjusted* OR (95% CI) Unadjusted OR (95% CI) Adjusted* OR (95% CI)
HIV status
Uninfected 1.0 1.0 1.0 1.0
Infected 2.7 (1.8 to 4.2) 1.8 (1.1 to 3.0) 3.1 (1.2 to 7.8) 2.8 (0.9 to 8.6)
Education
≤ Senior secondary 1.0 1.0
≥ Tertiary 1.6 (1.0 to 2.5) 1.1 (0.5 to 2.8)
Years since anal coital debut
≤ 7 1.0 1.0 1.0 1.0
≥ 8 1.6 (1.0 to 2.5) 1.6 (0.9 to 2.6) 3.0 (1.1 to 7.7) 2.8 (1.0 to 7.9)
Lifetime No. of receptive sex partners
≤ 10 1.0 1.0
≥ 11 1.2 (0.8 to 2.0) 3.0 (1.2 to 7.2)
Sexual position
Insertive 1.0 1.0
Receptive 2.0 (0.9 to 4.2) 7.9 (0.8 to 81.4)
Both 1.4 (0.8 to 2.3) 7.9 (1.0 to 60.9)
Concurrent sexual partnerships
None 1.0 1.0 1.0 1.0
Men only 2.1 (1.2 to 3.6) 2.3 (1.3 to 4.3) 2.3 (0.7 to 7.3) 2.6 (0.8 to 8.5)
Both men and women 0.8 (0.5 to 1.4) 1.0 (0.6 to 1.8) 1.2 (0.4 to 3.7) 1.5 (0.5 to 4.9)
Urethral STIs at last visit
No 1.0 1.0 1.0 1.0
Yes 0.6 (0.3 to 1.5) 0.8 (0.3 to 2.3) 3.3 (1.1 to 10.6) 5.7 (1.4 to 23.0)
External warts observed during HRA
No 1.0 1.0 1.0 1.0
Yes 8.2 (4.3 to 15.5) 7.3 (3.8 to 14.2) 10.2 (3.8 to 27.7) 8.9 (3.1 to 25.4)
NOTE. Bold indicates P , .05.
Abbreviations: HRA, high-resolution anoscopy; HSIL, high-grade squamous intraepithelial lesions; LSIL, low-grade squamous intraepithelial
lesions; OR, odds ratio; STIs, sexually transmitted infections, including Neisseria gonorrhea and Chlamydia trachomatis.
*Multinomial logistic regression adjusted for years since first anal sex, lifetime number of receptive sex partners, concurrent sexual partnerships,
urethral STIs, and external warts observed during HRA. Education and sexual position were not significant and did not improve the final model.
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APPENDIX
The TRUST Study Group is constituted as follows: Principal In-
vestigators: Manhattan Charurat (IHV, University of Maryland,
Baltimore, MD, USA), Julie Ake (MHRP, Walter Reed Army Institute
of Research, Silver Spring, MD, USA); Co-Investigators: Sylvia
Adebajo, Stefan Baral, Erik Billings, Trevor Crowell, George Eluwa,
Charlotte Gaydos, Sosthenes Ketende, Afoke Kokogho, Hongjie Liu,
Jennifer Malia, Olumide Makanjuola, Nelson Michael, Nicaise
Ndembi, Jean Njab, Rebecca Nowak, Oluwasolape Olawore, Zahra
Parker, Sheila Peel, Habib Ramadhani, Merlin Robb, Cristina
Rodriguez-Hart, Eric Sanders-Buell, Sodsai Tovanabutra, Erik Volz;
Institutions: Institute of Human Virology at the University of
Maryland School of Medicine (IHV-UMB), University of Maryland
School of Public Health (UMD SPH), Johns Hopkins Bloomberg School
of Public Health (JHSPH), Johns Hopkins University School of Medicine
(JHUSOM), U.S. Military HIV Research Program (MHRP), Walter
Reed Army Institute of Research (WRAIR), Henry M. Jackson
Foundation for the Advancement of Military Medicine (HJF), Henry
M. Jackson Foundation Medical Research International (HJFMRI),
Institute of Human Virology Nigeria (IHVN), International Centre for
Advocacy for the Right to Health (ICARH), The Initiative for Equal
Rights (TIERS), Population Council (Pop Council) Nigeria, Imperial
College London.
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